Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Bilthoven – page 102

1 718 clinical trials in Bilthoven, The Netherlands across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Bilthoven at a glance
1 718
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

1 718 trials in Bilthoven

Open in trial search

Hormone receptor positive HER2 negative breast cancer+1

Not recruiting

Study on Alpelisib and Fulvestrant for Advanced Breast Cancer in Patients with PIK3CA Mutation and Hormone-Receptor Positive, HER2 Negative Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:BOOG Study Center B.V.

Chronic lymphocytic leukaemia

Not recruiting

Study on Venetoclax, Ibrutinib, and Obinutuzumab for Chronic Lymphocytic Leukemia Patients Not in Complete Remission or with Detectable Bone Marrow Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Eosinophilic oesophagitis

Not recruiting

Study on the Effects of EP-104IAR and Tetracosactide for Adults with Eosinophilic Esophagitis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Tetracosactide
  • Sponsor:Eupraxia Pharmaceuticals Inc.

Malignant melanoma

Not recruiting

Study on Early Discontinuation of Nivolumab and Ipilimumab in Patients with Advanced Melanoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Lung neoplasm malignant

Not recruiting

Study of Patritumab Deruxtecan for Patients with Previously Treated Metastatic or Locally Advanced EGFR-Mutated Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Patritumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Colitis ulcerative

Not recruiting

Study on Vedolizumab for Patients with Active Ulcerative Colitis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Vedolizumab
  • Sponsor:Alimentiv Inc.

Malignant melanoma

Not recruiting

Study Comparing Naporafenib and Trametinib Combination to Other Therapies for Patients with Previously Treated Unresectable or Metastatic NRAS Mutant Melanoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Erasca Inc.

Transitional cell carcinoma

Not recruiting

Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Bicycletx Limited

Dry age-related macular degeneration

Not recruiting

Study on Long-Term Safety and Effects of Pegcetacoplan for Patients with Geographic Atrophy from Age-Related Macular Degeneration

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Apellis Pharmaceuticals Inc.

Kidney transplant rejection

Not recruiting

Study on Imlifidase for Highly Sensitized Patients with End-Stage Chronic Kidney Disease Awaiting Transplant

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Imlifidase
  • Sponsor:Hansa Biopharma AB

Multiple sclerosis

Not recruiting

Study on Personalized Ocrelizumab Dosing for Patients with Relapsing Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:Amsterdam UMC Stichting

Interstitial lung disease

Not recruiting

Study on BI 1015550 for Improving Lung Function in Patients with Progressive Fibrosing Interstitial Lung Diseases

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Bilthoven

What the registry says about research in the country

01 Infectious Disease Prevention

Research focusing on optimizing vaccine effectiveness against multiple infectious diseases, including studies on meningococcal disease and influenza in different age groups.

  • Meningococcal Disease Prevention
  • Influenza Vaccination Timing
  • Early Measles Protection

Novel approaches include investigating optimal vaccination timing and early immunization strategies for enhanced protection.

02 Oncology Research

Advanced studies in breast cancer treatment, examining innovative therapeutic combinations for hormone receptor-positive cases.

  • Hormone Receptor Positive Breast Cancer
  • CDK 4/6 Inhibition Therapy
  • Sequential Treatment Strategies

Investigations focus on optimizing treatment sequences to improve progression-free survival rates.

03 Surgical Interventions

Clinical research examining surgical treatments combined with antibiotic therapy for improved patient outcomes.

  • Perianal Abscess Management
  • Combined Treatment Approaches
  • Fistula Prevention

Studies aim to enhance surgical outcomes through innovative combination therapies.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.